

Maria Fiammetta Romano

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/266709/publications.pdf>

Version: 2024-02-01

35
papers

1,095
citations

567281

15
h-index

434195

31
g-index

35
all docs

35
docs citations

35
times ranked

1756
citing authors

#	ARTICLE	IF	CITATIONS
1	Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: the challenge ahead. <i>Carcinogenesis</i> , 2015, 36, S254-S296.	2.8	239
2	Rapamycin stimulates apoptosis of childhood acute lymphoblastic leukemia cells. <i>Blood</i> , 2005, 106, 1400-1406.	1.4	146
3	Rapamycin inhibits doxorubicin-induced NF- κ B/Rel nuclear activity and enhances the apoptosis of melanoma cells. <i>European Journal of Cancer</i> , 2004, 40, 2829-2836.	2.8	130
4	A regulatory role for the co-chaperone FKBP51s in PD-L1 expression in glioma. <i>Oncotarget</i> , 2017, 8, 68291-68304.	1.8	71
5	FKBP51 employs both scaffold and isomerase functions to promote NF- κ B activation in melanoma. <i>Nucleic Acids Research</i> , 2015, 43, 6983-6993.	14.5	68
6	Overexpression of chromatin assembly factor α p60, poly(ADP-ribose) polymerase 1 and nestin predicts metastasizing behaviour of oral cancer. <i>Histopathology</i> , 2012, 61, 1089-1105.	2.9	40
7	FKBP51 and the NF- κ B regulatory pathway in cancer. <i>Current Opinion in Pharmacology</i> , 2011, 11, 288-293.	3.5	38
8	Disruptive environmental chemicals and cellular mechanisms that confer resistance to cell death. <i>Carcinogenesis</i> , 2015, 36, S89-S110.	2.8	33
9	FKBP51 increases the tumour-promoter potential of TGF β . <i>Clinical and Translational Medicine</i> , 2014, 3, 1.	4.0	31
10	FKBP51 Immunohistochemical Expression: A New Prognostic Biomarker for OSCC?. <i>International Journal of Molecular Sciences</i> , 2017, 18, 443.	4.1	31
11	Tirofiban induces VEGF production and stimulates migration and proliferation of endothelial cells. <i>Vascular Pharmacology</i> , 2014, 61, 63-71.	2.1	29
12	Effects Of Glycoprotein IIb/IIIa Antagonists: Anti Platelet Aggregation And Beyond. <i>Current Drug Metabolism</i> , 2016, 17, 194-203.	1.2	28
13	Cell stemness, epithelial-to-mesenchymal transition, and immunoevasion: Intertwined aspects in cancer metastasis. <i>Seminars in Cancer Biology</i> , 2020, 60, 181-190.	9.6	26
14	Pleiotropic roles in cancer biology for multifaceted proteins FKBP51. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2015, 1850, 2061-2068.	2.4	25
15	Immunomodulatory pathways regulate expression of a spliced FKBP51 isoform in lymphocytes of melanoma patients. <i>Pigment Cell and Melanoma Research</i> , 2015, 28, 442-452.	3.3	23
16	Increased CD154 Expression in Uninfected Infants Born to HIV-Positive Mothers Exposed to Antiretroviral Prophylaxis. <i>Viral Immunology</i> , 2006, 19, 363-372.	1.3	15
17	Tirofiban counteracts endothelial cell apoptosis through the VEGF/VEGFR2/pAkt axis. <i>Vascular Pharmacology</i> , 2016, 80, 67-74.	2.1	15
18	Role of ZNF224 in cell growth and chemoresistance of chronic lymphocytic leukemia. <i>Human Molecular Genetics</i> , 2016, 26, ddw427.	2.9	14

#	ARTICLE	IF	CITATIONS
19	The splicing FK506-binding protein-51 isoform plays a role in glioblastoma resistance through programmed cell death ligand-1 expression regulation. <i>Cell Death Discovery</i> , 2019, 5, 137.	4.7	14
20	PD-L1 Expression Fluctuates Concurrently with Cyclin D in Glioblastoma Cells. <i>Cells</i> , 2021, 10, 2366.	4.1	13
21	FKBP51s signature in peripheral blood mononuclear cells of melanoma patients as a possible predictive factor for immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 1143-1151.	4.2	12
22	Manipulation of the Immune System for Cancer Defeat: A Focus on the T Cell Inhibitory Checkpoint Molecules. <i>Current Medicinal Chemistry</i> , 2020, 27, 2402-2448.	2.4	12
23	Alternative macrophage polarisation associated with resistance to anti-PD1 blockade is possibly supported by the splicing of FKBP51 immunophilin in melanoma patients. <i>British Journal of Cancer</i> , 2020, 122, 1782-1790.	6.4	11
24	Combining Magnetic Resonance Imaging with Systemic Monocyte Evaluation for the Implementation of GBM Management. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3797.	4.1	6
25	FKBPs: opportunistic modifiers or active players in cancer?. <i>Current Opinion in Pharmacology</i> , 2011, 11, 279-280.	3.5	5
26	Targeting TGFbeta-mediated processes in cancer. <i>Current Opinion in Drug Discovery & Development</i> , 2009, 12, 253-63.	1.9	5
27	Cellular and Molecular Background Underlying the Diversity in Therapeutic Responses Between Primary Tumours and Metastases. <i>Current Medicinal Chemistry</i> , 2014, 21, 1631-1638.	2.4	4
28	Molecular Aspects of FKBP51 that Enable Melanoma Dissemination. <i>Current Molecular Pharmacology</i> , 2015, 9, 141-147.	1.5	4
29	Tirofiban Positively Regulates β_1 Integrin and Favours Endothelial Cell Growth on Polylactic Acid Biopolymer Vascular Scaffold (BVS). <i>Journal of Cardiovascular Translational Research</i> , 2018, 11, 201-209.	2.4	3
30	Thrombocytopenia Complicating Transcatheter Aortic Valve Implantation: Differences Between Two New-Generation Devices. <i>Journal of Cardiovascular Translational Research</i> , 2021, 14, 1104-1113.	2.4	3
31	Expansion of a lymphocyte subset expressing a spliced FKBP51 isoform in melanoma patients.. <i>Journal of Clinical Oncology</i> , 2015, 33, e20070-e20070.	1.6	1
32	Editorial (Thematic Issue: Molecular Aspects of Cancer Resistance to Biological and Non- Biological) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	2.4	0
33	Comparison of Biolimus Versus Everolimus for Drug-Eluting Stents in the Percutaneous Treatment of Infra-Inguinal Arterial Disease. <i>Current Vascular Pharmacology</i> , 2017, 15, 257-264.	1.7	0
34	Eradication of CSCs: the roadmap for curing cancer. <i>Oncoscience</i> , 2020, 7, 70-72.	2.2	0
35	Eradication of CSCs: the roadmap for curing cancer. <i>Oncoscience</i> , 2020, 7, 70-72.	2.2	0